Related Experiment Video
Updated: Dec 30, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.4K
Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression
Devin K Binder1, Detlev Boison2, Tore Eid3
1Division of Biomedical Sciences, School of Medicine, Center for Glial-Neuronal Interactions, University of California, Riverside, CA, USA.
Epilepsy Currents
|January 16, 2020
Summary
This review summarizes advances in epilepsy prevention research since 2016, focusing on goals for stopping epilepsy development and progression. It highlights recent progress and emerging areas in epilepsy research benchmarks.
Area of Science:
- Epilepsy research
- Neuroscience
- Preventive medicine
Background:
- The 2014 Epilepsy Research Benchmarks established goals for epilepsy prevention.
- A previous progress summary was published in 2016.
- Advances in understanding epilepsy development and progression are crucial.
Purpose of the Study:
- To review key advances in Area II of the Epilepsy Research Benchmarks since 2016.
- To highlight progress in preventing epilepsy development and progression.
- To identify emerging research areas in epilepsy prevention.
Main Methods:
- Literature review of research published since 2016.
- Analysis of progress in relation to the 2014 benchmarks.
- Identification of research trends and opportunities.
Main Results:
- Significant progress has been made in understanding the mechanisms underlying epilepsy development.
- New therapeutic targets for epilepsy prevention have been identified.
- Research in areas like neuroinflammation and genetic factors has advanced.
Conclusions:
- Continued research is vital for achieving the goals of epilepsy prevention.
- Translational research is needed to move findings from bench to bedside.
- Collaboration and focused investment will accelerate progress in preventing epilepsy.
Keywords:
NINDS benchmarks for epilepsy researchbenchmarksepilepsyepilepsy preventionepileptogenesispreventing epilepsyprevention clinical trialsprogress in epilepsy researchMore Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:13Seizures: Classification
1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
750
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
750
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
555
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
555